Phase II Win For Merck KGaA/Avillion Psoriasis Drug May Be Too Late
Sonelokinab Targets Both IL-17A and IL-17F
The German major is looking for a partner to advance its IL-17A/IL-17F nanobody sonelokinab for psoriasis but the search could be tricky given the strength of Novartis's Cosentyx and Eli Lilly's Taltz, while UCB's IL-17A and IL-17F inhibitor bimekizumab is likely to be approved soon.
